Adjuavnt tyrosinase peptide vaccination in patients with resected stage III/IV melanoma.

被引：0

作者：

Letsch, A.

Scheibenbogen, C.

Fluck, M.

Asemissen, A.

Nagorsen, D.

Thiel, E.

Keilholz, U.

机构：

[1] CBF, Charite, Hematol & Oncol, Berlin, Germany

[2] Fachklin Hornheide, Munster, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：117S / 117S

页数：1

共 50 条

[21] Safety of pembrolizumab for resected stage III melanoma [J].

Pham, F. ;

Dalle, S. .

EXPERT OPINION ON DRUG SAFETY, 2020, 19 (10) :1221-1227

[22] Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. [J].

Hawkins, R. E. ;

Dangoor, A. ;

Keilholz, U. ;

Schadendorf, D. ;

Harris, A. ;

Ottensmeier, C. ;

Smyth, J. ;

Hoffmnan, K. ;

Anderson, R. ;

Pearce, G. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :460S-460S

[23] A phase II clinical trial of a novel combinatorial antitumor immunotherapy for patients with high-risk resected stage III and metastatic melanoma. [J].

Riker, A. I. ;

Alsfeld, L. C. ;

Harrison, M. ;

Foxworth, D. ;

Lee, Q. ;

Rossi, G. R. ;

Tennant, L. ;

Ramsey, W. J. ;

Vahanian, N. N. ;

Link, C. J. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[24] Prognostic biomarkers in stage II-III melanoma. [J].

Rizk, Emanuelle M. ;

Gartrell, Robyn D. ;

Chen, Andrew ;

Chang, Rui ;

Marks, Douglas K. ;

Esancy, Camden L. ;

Taback, Bret ;

Horst, Basil A. ;

Drake, Charles G. ;

Rabadan, Raul ;

Saenger, Yvonne M. .

CANCER RESEARCH, 2020, 80 (19) :49-50

[25] The gut microbiome is associated with recurrence free survival in patients with resected Stage III or Stage IV melanoma treated with immune checkpoint inhibitors [J].

Usyk, Mykhaylo ;

Hayes, Richard B. ;

Knight, Rob ;

Gonzalez, Antonio ;

Li, Huilin ;

Osman, Iman ;

Weber, Jeffrey S. ;

Ahn, Jiyoung .

CANCER RESEARCH, 2024, 84 (06)

[26] Adjuvant multi-peptide vaccination in high risk stage II-III melanoma patients [J].

Filipazzi, Paola ;

Cova, Agata ;

Sovena, Gloria ;

Squarcina, Paola ;

Pilla, Lorenzo ;

Patuzzo, Roberto ;

Maurichi, Andrea ;

Cutolo, Gianluca ;

Castelli, Chiara ;

Casati, Chiara ;

Tragni, Gabrina ;

Deho, Paola ;

Santinami, Mario ;

Parmiani, Giorgio ;

Rivoltini, Licia .

JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) :894-894

[27] Mixture-cure modeling for resected stage III/IV melanoma in the phase III CheckMate 238 trial [J].

Weber, J. S. ;

Kurt, M. ;

Edmondson-Jones, M. ;

Amadi, A. ;

Lobo, M. ;

Moshyk, A. ;

Kotapati, S. ;

Mohr, P. .

ANNALS OF ONCOLOGY, 2019, 30 :542-542

[28] Impact of adjuvant immunotherapy in resected stage II/III/IV melanoma: A single center experience [J].

Sevillano Tripero, Alberto Rafael ;

Ortiz, Carolina ;

Lostes, Julia ;

Bodet, Domingo ;

Ferrandiz, Carla ;

Bassas, Patricia ;

Chiquillo, Paula ;

Villacampa, Guillermo ;

Vega-Cano, Kreina Sharela ;

Garcia-Patos, Vicente ;

Recio, Juan ;

Munoz-Couselo, Eva .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[29] Phase 2 study of talabostat and cisplatin in stage IV melanoma. [J].

Uprichard, MJ ;

O'Day, SJ ;

Pavlick, AC ;

Richards, DA ;

Frenette, G ;

Stephenson, J ;

Anthony, S ;

Pacciucci, PA ;

Vrhovac, V ;

Cunningham, C .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :725S-725S

[30] Phase I trial of human tyrosinase DNA vaccination in dogs with advanced malignant melanoma. [J].

Bergman, PJ ;

McKnight, J ;

Novosad, A ;

Chamey, S ;

Farrelly, J ;

Jeffers, Y ;

Egan, M ;

Craft, D ;

Gallardo, H ;

Riviere, I ;

Wulderk, M ;

Hohenhaus, A ;

Houghton, A ;

Wolchok, J .

CLINICAL CANCER RESEARCH, 2001, 7 (11) :3754S-3754S

← 1 2 3 4 5 →